| P/E (FY) | — | Sales (TTM) | $86.9M |
| Earnings (TTM) | -$1.5M | ROE | −18.19% |
| Net Margin | −5.75% | ROIC | −1.90% |
| Debt / Equity | 1.17 | TD / EBITDA | 9.55 |
| EPS Growth 3Y | — | Sales Growth 3Y | 55.53% |
Eton Pharmaceuticals develops and commercializes treatments for rare diseases. Its commercial products include Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle and Khindivi for adrenal insufficiency, Galzin for Wilson disease, PKU Golike for phenylketonuria, and Nitisinone for tyrosinemia type 1. Late-stage candidates include ET-600 for diabetes insipidus, Amglidia for neonatal diabetes, and a ZENEO hydrocortisone autoinjector for adrenal crisis. It is based in Deer Park, Illinois.
| Market Cap | $1.28B | Trading Days | 1931 |
| 52W High | 47.16 |
| 52W Low | 13.78 |
| % Off High | −1.06% |
| YTD | 175.93% | 1Y | 210.45% |
| 3Y | 1729.80% | 5Y | 739.21% |
| Since incept. (ann.) | 29.81% |
Product Sales And Royalties 96% · License 4%
| Ann. Volatility (1Y) | 56.40% | Ann. Volatility (3Y) | 66.01% |
| Sharpe (1Y) | 2.32 | Sharpe (3Y) | 1.77 |
| Max Drawdown (1Y) | −36.17% | Max Drawdown (3Y) | −45.65% |
| Beta (3Y, vs SPY) | −0.44 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ARDX | ARDELYX, INC. | $1.26B | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.23B | — |
| OPK | OPKO HEALTH, INC. | $1.23B | — |
| AVLN | Avalyn Pharma Inc. | $1.22B | — |
| MNKD | MANNKIND CORP | $1.21B | 195.5 |
| MLTX | MoonLake Immunotherapeutics | $1.38B | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.16B | 20.8 |
| XERS | Xeris Biopharma Holdings, Inc. | $1.42B | — |
| PRGO | PERRIGO Co plc | $1.43B | — |
| WVE | Wave Life Sciences Ltd. | $1.13B | — |
| SDGR | Schrodinger, Inc. | $1.12B | — |